FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912158807> ?p ?o ?g. }

• W2912158807 endingPage "e748" @default.
• W2912158807 startingPage "e740" @default.
• W2912158807 abstract "Abstract Background NUT carcinoma is a rare aggressive disease caused by BRD4/3-NUT fusion, and C-MYC upregulation plays a key role in the pathogenesis. Here, we report on the clinicopathological characteristics of Korean patients with NUT carcinoma and the in vitro efficacy of MYC-targeting agents against patient-derived NUT carcinoma cell lines. Materials and Methods Thirteen patients with NUT carcinoma were evaluated for p53, C-MYC, epidermal growth factor receptor (EGFR), HER2, and programmed cell death ligand 1 (PD-L1) by immunohistochemistry. The half maximal inhibitory concentration (IC50) values of NUT carcinoma cell lines (SNU-2972-1, SNU-3178S, HCC2429, and Ty-82) were determined using MYC-targeting agents, including bromodomain and extraterminal (BET) inhibitors (I-BET, OTX-015, AZD5153) and histone deacetylase (HDAC) inhibitors (vorinostat, romidepsin, panobinostat, CUDC-907). Results Primary tumor sites included head and neck (n = 9) and lung (n = 4). The patient age ranged from 8 to 73 years with the male/female ratio of 1.2:1. Nine patients died at 3–23.6 months (median, 10.6) after diagnosis. Eight patients had been misdiagnosed initially with other diseases. One patient with metastatic NUT carcinoma who received mass excision plus metastasectomy followed by chemoradiotherapy was a long-term survivor (&gt;27 months). Although expressions of C-MYC (8/12, 73%) and p53 (12/12, 100%) were commonly observed, EGFR, HER2, and PD-L1 expressions were observed in 2 of 7 (29%), 2 of 8 (25%), and 1 of 12 (8.3%) patients, respectively. BET and HDAC inhibitors showed variable but limited in vitro efficacy. However, a dual HDAC/PI3K inhibitor, CUDC-907, was most potent against NUT carcinoma cells, with an IC50 of 5.5–9.0 pmol/L. Consistent with these findings, kinome short interfering RNA screening showed a positive hit for PI3KCA in NUT carcinoma cells. Panobinostat (IC50, 0.4–1.3 nmol/L) and a bivalent BET inhibitor, AZD5153 (IC50, 3.7–8.2 nmol/L), also showed remarkable efficacies. Conclusion East Asian patients with NUT carcinoma showed dismal survival outcomes like Western patients, and CUDC-907 might be promising in NUT carcinoma treatment." @default.
• W2912158807 created "2019-02-21" @default.
• W2912158807 creator A5010364211 @default.
• W2912158807 creator A5016978421 @default.
• W2912158807 creator A5020952516 @default.
• W2912158807 creator A5021363331 @default.
• W2912158807 creator A5024891671 @default.
• W2912158807 creator A5024929630 @default.
• W2912158807 creator A5031054461 @default.
• W2912158807 creator A5039140763 @default.
• W2912158807 creator A5041612441 @default.
• W2912158807 creator A5053331766 @default.
• W2912158807 creator A5058041278 @default.
• W2912158807 creator A5058521062 @default.
• W2912158807 creator A5060716452 @default.
• W2912158807 creator A5070098382 @default.
• W2912158807 creator A5076726962 @default.
• W2912158807 creator A5080295544 @default.
• W2912158807 creator A5087839513 @default.
• W2912158807 creator A5091900101 @default.
• W2912158807 date "2019-01-29" @default.
• W2912158807 modified "2023-10-18" @default.
• W2912158807 title "Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study" @default.
• W2912158807 cites W1555984726 @default.
• W2912158807 cites W1822770076 @default.
• W2912158807 cites W1911253268 @default.
• W2912158807 cites W1998469647 @default.
• W2912158807 cites W1999948240 @default.
• W2912158807 cites W2009029547 @default.
• W2912158807 cites W2019607817 @default.
• W2912158807 cites W2019849287 @default.
• W2912158807 cites W2029572722 @default.
• W2912158807 cites W2041535798 @default.
• W2912158807 cites W2054323652 @default.
• W2912158807 cites W2055245684 @default.
• W2912158807 cites W2110721869 @default.
• W2912158807 cites W2120572492 @default.
• W2912158807 cites W2125828985 @default.
• W2912158807 cites W2134549313 @default.
• W2912158807 cites W2144858115 @default.
• W2912158807 cites W2157597210 @default.
• W2912158807 cites W2158125144 @default.
• W2912158807 cites W2169944837 @default.
• W2912158807 cites W2171595327 @default.
• W2912158807 cites W2298793032 @default.
• W2912158807 cites W2508500919 @default.
• W2912158807 cites W2514318120 @default.
• W2912158807 cites W2516657620 @default.
• W2912158807 cites W2520148131 @default.
• W2912158807 cites W2561238268 @default.
• W2912158807 cites W2588103136 @default.
• W2912158807 cites W2588319976 @default.
• W2912158807 cites W2672188854 @default.
• W2912158807 cites W2792323180 @default.
• W2912158807 doi "https://doi.org/10.1634/theoncologist.2018-0477" @default.
• W2912158807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6693698" @default.
• W2912158807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30696721" @default.
• W2912158807 hasPublicationYear "2019" @default.
• W2912158807 type Work @default.
• W2912158807 sameAs 2912158807 @default.
• W2912158807 citedByCount "35" @default.
• W2912158807 countsByYear W29121588072019 @default.
• W2912158807 countsByYear W29121588072020 @default.
• W2912158807 countsByYear W29121588072021 @default.
• W2912158807 countsByYear W29121588072022 @default.
• W2912158807 countsByYear W29121588072023 @default.
• W2912158807 crossrefType "journal-article" @default.
• W2912158807 hasAuthorship W2912158807A5010364211 @default.
• W2912158807 hasAuthorship W2912158807A5016978421 @default.
• W2912158807 hasAuthorship W2912158807A5020952516 @default.
• W2912158807 hasAuthorship W2912158807A5021363331 @default.
• W2912158807 hasAuthorship W2912158807A5024891671 @default.
• W2912158807 hasAuthorship W2912158807A5024929630 @default.
• W2912158807 hasAuthorship W2912158807A5031054461 @default.
• W2912158807 hasAuthorship W2912158807A5039140763 @default.
• W2912158807 hasAuthorship W2912158807A5041612441 @default.
• W2912158807 hasAuthorship W2912158807A5053331766 @default.
• W2912158807 hasAuthorship W2912158807A5058041278 @default.
• W2912158807 hasAuthorship W2912158807A5058521062 @default.
• W2912158807 hasAuthorship W2912158807A5060716452 @default.
• W2912158807 hasAuthorship W2912158807A5070098382 @default.
• W2912158807 hasAuthorship W2912158807A5076726962 @default.
• W2912158807 hasAuthorship W2912158807A5080295544 @default.
• W2912158807 hasAuthorship W2912158807A5087839513 @default.
• W2912158807 hasAuthorship W2912158807A5091900101 @default.
• W2912158807 hasBestOaLocation W29121588071 @default.
• W2912158807 hasConcept C104317684 @default.
• W2912158807 hasConcept C126322002 @default.
• W2912158807 hasConcept C143998085 @default.
• W2912158807 hasConcept C185592680 @default.
• W2912158807 hasConcept C2776262904 @default.
• W2912158807 hasConcept C2777546739 @default.
• W2912158807 hasConcept C2778305200 @default.
• W2912158807 hasConcept C2778424827 @default.
• W2912158807 hasConcept C2781462825 @default.
• W2912158807 hasConcept C502942594 @default.
• W2912158807 hasConcept C509974204 @default.
• W2912158807 hasConcept C55493867 @default.

• next